Table 1.
Study subject characteristics
| Patient/donor | Age, y | Sex | Source; % blasts | Disease* | Status | Cytogenetics |
|---|---|---|---|---|---|---|
| AML1 | 79 | M | LP; 87% | AML-M1 | Untreated | +8 |
| AML2 | 61 | M | PB; 66% | AML-M2 | Relapse | +14; FLT3+ (ITD) |
| AML3 | 73 | F | PB; 64% | AML-M5 | Refractory | −5,−12 |
| AML4 | 53 | M | LP; 96% | AML-M5 | Untreated | +8; t(9;11) |
| AML5 | 24 | M | LP; 85% | AML-M1 | Untreated | FLT3+ (ITD) |
| AML6A2− | 41 | F | PB; 98% | AML-M1 | Untreated | Diploid |
| AML7† | 38 | M | PB; 65% | AML-M7 | Refractory | −1,−5,−7,−9,−21 |
| AML8 | 81 | F | PB; 92% | AML-M1 | Untreated | Diploid |
| AML9 | 64 | F | PB; 70% | AML-M1 | Untreated | Diploid |
| ALL1‡ | 65 | F | BM; 78% | B-ALL | Untreated | −2,−3,−4,−7,−9 |
| ND1 | 34 | M | PB | NA | NA | NA |
| ND2 | 42 | F | PB | NA | NA | NA |
| ND3 | 35 | F | PB | NA | NA | NA |
| ND4 | 38 | M | PB | NA | NA | NA |
| ND5 | 32 | M | BM | NA | NA | NA |
| ND6 | 53 | M | BM | NA | NA | NA |
| ND7 | 26 | M | BM | NA | NA | NA |
| ND8 | 30 | M | BM | NA | NA | NA |
| ND9 | 58 | F | BM | NA | NA | NA |
| ND10 | 31 | M | BM | NA | NA | NA |
A2− superscript indicates HLA-A2–negative; LP, leukapheresis collection; PB, peripheral blood; BM, bone marrow; ND, normal donor; and NA, not applicable.
*
FAB subtype.
†
Antecedent myelodysplastic syndrome.
‡
Ph-chromosome–negative.